Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT01420705 Completed - Asthma Clinical Trials

Bacille Calmette-Guérin (BCG) Vaccine and Atopy

Start date: October 2011
Phase: N/A
Study type: Observational

The prevalence of asthma and allergic diseases is increasing worldwide. Infections and vaccinations in childhood may have an impact on the subsequent development of asthma and allergy. In Guinea-Bissau, the investigators previously found that Bacille Calmette-Guérin (BCG) vaccine was associated with reduction in atopy. Since then the investigators have conducted a randomised trial of BCG vaccine given at birth to low birth-weight infants. The present study aims to follow up children enrolled in the BCG randomised trial to assess for asthma and allergy later in childhood. Based on previous observations, the investigators expect children allocated to receive BCG at birth will have a reduction in allergy profile when compared to children who did not receive BCG at birth.

NCT ID: NCT01408511 Completed - Atopic Dermatitis Clinical Trials

HPA Axis Study in Adults

Start date: July 19, 2011
Phase: Phase 2
Study type: Interventional

A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in adults with atopic dermatitis.

NCT ID: NCT01407510 Completed - Atopic Dermatitis Clinical Trials

HPA Axis Study in Japanese Adults

Start date: May 9, 2011
Phase: Phase 2
Study type: Interventional

A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.

NCT ID: NCT01402414 Terminated - Atopic Dermatitis Clinical Trials

Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis

Start date: April 2011
Phase: N/A
Study type: Interventional

In this controlled crossover study we aim to compare the efficacy of narrow-band UVB (NB-UVB) with bath-PUVA and NB-UVB plus salt water baths in atopic dermatitis.

NCT ID: NCT01393158 Completed - Atopic Dermatitis Clinical Trials

Apremilast for Atopic Dermatitis - A Pilot Study in Adults

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.

NCT ID: NCT01385657 Completed - Atopic Dermatitis Clinical Trials

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Start date: July 31, 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT01385527 Withdrawn - Atopic Dermatitis Clinical Trials

Pediatric Atopic Dermatitis (AD) Internet Survey

Start date: June 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.

NCT ID: NCT01375205 Completed - Atopic Dermatitis Clinical Trials

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Start date: June 2011
Phase: N/A
Study type: Interventional

The goal of this study is to determine what effect Cetaphil® Restoraderm® system has on babies' skin versus Johnson & Johnson baby lotion and skin cleanser.

NCT ID: NCT01368315 Withdrawn - Atopic Dermatitis Clinical Trials

CT 327 in the "Atopy Patch Test" Model

CT327 AD01-09
Start date: n/a
Phase: Phase 1
Study type: Interventional

A Randomized, Double-Blind, Phase I, Single-Center Study on the Efficacy and Safety of CT 327 in the Atopy Patch Test model.

NCT ID: NCT01366846 Completed - Food Allergy Clinical Trials

Persistence of Oral Tolerance to Peanut

LEAP-On
Start date: December 2012
Phase: Phase 2
Study type: Interventional

ITN049AD (LEAP-On) Study is a continuation of the ITN032AD LEAP Study (NCT00329784). Peanut Allergy, a recognized public health concern, is a common and potentially life-threatening food allergy for which there is no treatment. ITN032AD (LEAP) Study evaluated whether early exposure to peanut promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema. ITN049AD (LEAP-On) Study will evaluate persistent tolerance to peanut by assessing the effect of twelve months of cessation of peanut consumption in LEAP Study participants who consumed peanut and those who avoided peanut over the previous five years.